Follow the 메디포스트 share price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 메디포스트 has recorded 66 insider filings. The latest transaction was reported on 20 January 2026 (Purchase). Among the most active insiders: 스카이메디. The full history is openly available.
66
Insider Decl.
n/a
Thresholds
n/a
15 ops.
Buy Volume
n/a
40 ops.
Sell Volume
5Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
메디포스트 is a company in the health and pharmaceutical sector, listed on the XKRX. It focuses on the development of cell therapies and biopharmaceutical products.